{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:43:13Z","timestamp":1791650593734,"version":"4.3.4"},"reference-count":48,"publisher":"Japan Atherosclerosis Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2025,4,1]]},"DOI":"10.5551\/jat.64953","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T22:17:11Z","timestamp":1728080231000},"page":"421-438","source":"Crossref","is-referenced-by-count":10,"title":["Serum Lipoprotein(a) Levels and Their Association with Atherosclerotic Cardiovascular Disease in Japan"],"prefix":"10.5551","volume":"32","author":[{"given":"Emi","family":"Fujii","sequence":"first","affiliation":[{"name":"Medical Affairs Division, Novartis Pharma K.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Ako","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kitasato University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Medical Affairs Division, Novartis Pharma K.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutoshi","family":"Toda","sequence":"additional","affiliation":[{"name":"Medical Affairs Division, Novartis Pharma K.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Iekushi","sequence":"additional","affiliation":[{"name":"Medical Affairs Division, Novartis Pharma K.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuya","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rinku General Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","unstructured":"1) The Ministry of Health Labor and Welfare: Demographic statistics for Japan. 2018 Available from https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/jinkou\/geppo\/nengai18\/dl\/gaikyou30.pdf; last accessed: August 2022"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Sun W, Yamagishi K and Iso H: Current Status of Low-Density Lipoprotein Cholesterol and Cardiovascular Diseases in Japan. J Atheroscler Thromb, 2023; 30: 432-433","DOI":"10.5551\/jat.ED217"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Teramoto T: Is \u201cThe Japan Diet\u201d Cardioprotective? J Atheroscler Thromb, 2017; 24: 388-389","DOI":"10.5551\/jat.ED061"},{"key":"4","unstructured":"4) Sata M and Okamura T: Trends in the serum cholesterol level and dyslipidemia in Japan. Japanese Journal of Cardiovascular Disease Prevention, 2018; 53: 220-226"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Tsimikas S: Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk. Curr Opin Endocrinol Diabetes Obes, 2016; 23: 157-164","DOI":"10.1097\/MED.0000000000000237"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Minami Y, Kinoshita D, Muramatsu Y, Nagata T and Ako J: Role of Lipoprotein(a) in Cardiovascular Disease: A Review of Clinical Practice. Journal of Asian Pacific Society of Cardiology, 2022; 1: e11, 2022","DOI":"10.15420\/japsc.2021.31"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Boffa MB: Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis. Atherosclerosis, 2022; 349: 72-81","DOI":"10.1016\/j.atherosclerosis.2022.04.009"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Craig WY, Neveux LM, Palomaki GE, Cleveland MM and Haddow JE: Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem, 1998; 44: 2301-2306","DOI":"10.1093\/clinchem\/44.11.2301"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG and Danesh J: Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. Jama, 2009; 302: 412-423","DOI":"10.1001\/jama.2009.1063"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Langsted A, Kamstrup PR and Nordestgaard BG: High lipoprotein(a) and high risk of mortality. Eur Heart J, 2019; 40: 2760-2770","DOI":"10.1093\/eurheartj\/ehy902"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Waldeyer C, Makarova N, Zeller T, Schnabel RB, Brunner FJ, J\u00f8rgensen T, Linneberg A, Niiranen T, Salomaa V, Jousilahti P, Yarnell J, Ferrario MM, Veronesi G, Brambilla P, Signorini SG, Iacoviello L, Costanzo S, Giampaoli S, Palmieri L, Meisinger C, Thorand B, Kee F, Koenig W, Ojeda F, Kontto J, Landmesser U, Kuulasmaa K and Blankenberg S: Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. Eur Heart J, 2017; 38: 2490-2498","DOI":"10.1093\/eurheartj\/ehx166"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Naito R, Daida H, Masuda D, Harada-Shiba M, Arai H, Bujo H, Ishibashi S, Koga N, Oikawa S and Yamashita S: Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study. J Atheroscler Thromb, 2022; 29: 1188-1200","DOI":"10.5551\/jat.63019"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Kamstrup PR, Tybjaerg-Hansen A, Steffensen R and Nordestgaard BG: Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. Jama, 2009; 301: 2331-2339","DOI":"10.1001\/jama.2009.801"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Nordestgaard BG, Chapman MJ, Ray K, Bor\u00e9n J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokg\u00f6zoglu L and Tybj\u00e6rg-Hansen A: Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J, 2010; 31: 2844-2853","DOI":"10.1093\/eurheartj\/ehq386"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Tsimikas S and Marcovina SM: Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds: JACC Review Topic of the Week. J Am Coll Cardiol, 2022; 80: 934-946","DOI":"10.1016\/j.jacc.2022.06.019"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG and Orringer CE: Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol, 2019; 13: 374-392","DOI":"10.1016\/j.jacl.2019.04.010"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) O\u2019Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, \u010ce\u0161ka R, Ezhov MV, Jukema JW, Jensen HK, Tokg\u00f6zo\u011flu SL, Mach F, Huber K, Sever PS, Keech AC, Pedersen TR and Sabatine MS: Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation, 2019; 139: 1483-1492","DOI":"10.1161\/CIRCULATIONAHA.118.037184"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, Umemoto S, Egusa G, Ohmura H, Okamura T, Kihara S, Koba S, Saito I, Shoji T, Daida H, Tsukamoto K, Deguchi J, Dohi S, Dobashi K, Hamaguchi H, Hara M, Hiro T, Biro S, Fujioka Y, Maruyama C, Miyamoto Y, Murakami Y, Yokode M, Yoshida H, Rakugi H, Wakatsuki A, Yamashita S, Committee for E and Clinical Management of A: Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. J Atheroscler Thromb, 2018; 25: 846-984","DOI":"10.5551\/jat.GL2017"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Mitani H, Suzuki K, Ako J, Iekushi K, Majewska R, Touzeni S and Yamashita S: Achievement Rates for Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Atherosclerotic Cardiovascular Disease in a Real-World Setting in Japan. J Atheroscler Thromb, 2023; 30: 1622-1634","DOI":"10.5551\/jat.63940"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Laurent T, Simeone J, Kuwatsuru R, Hirano T, Graham S, Wakabayashi R, Phillips R and Isomura T: Context and Considerations for Use of Two Japanese Real-World Databases in Japan: Medical Data Vision and Japanese Medical Data Center. Drugs Real World Outcomes, 2022; 9: 175-187","DOI":"10.1007\/s40801-022-00296-5"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Umeda T, Hayashi A, Harada A, Okuyama K, Baxter CA, Tokita S and Teramoto T: Low-Density Lipoprotein Cholesterol Goal Attainment Rates by Initial Statin Monotherapy Among Patients With Dyslipidemia and High Cardiovascular Risk in Japan- A Retrospective Database Analysis. Circ J, 2018; 82: 1605-1613","DOI":"10.1253\/circj.CJ-17-0971"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Yeang C, Karwatowska-Prokopczuk E, Su F, Dinh B, Xia S, Witztum JL and Tsimikas S: Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol. J Am Coll Cardiol, 2022; 79: 1035-1046","DOI":"10.1016\/j.jacc.2021.12.032"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, Shapiro MD, Stroes ES, Moriarty PM, Nordestgaard BG, Xia S, Guerriero J, Viney NJ, O\u2019Dea L and Witztum JL: Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J Med, 2020; 382: 244-255","DOI":"10.1056\/NEJMoa1905239"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Nissen SE, Wolski K, Cho L, Nicholls SJ, Kastelein J, Leitersdorf E, Landmesser U, Blaha M, Lincoff AM, Morishita R, Tsimikas S, Liu J, Manning B, Kozlovski P, Lesogor A, Thuren T, Shibasaki T, Matei F, Silveira FS, Meunch A, Bada A, Vijan V, Bruun NE and Nordestgaard BG: Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease. Open Heart, 2022; 9: e002060","DOI":"10.1136\/openhrt-2022-002060"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Madsen CM, Kamstrup PR, Langsted A, Varbo A and Nordestgaard BG: Lipoprotein(a)-Lowering by 50 mg\/dL (105 nmol\/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study. Arterioscler Thromb Vasc Biol, 2020; 40: 255-266","DOI":"10.1161\/ATVBAHA.119.312951"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Patel AP, Wang M, Pirruccello JP, Ellinor PT, Ng K, Kathiresan S and Khera AV: Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank. Arterioscler Thromb Vasc Biol, 2021; 41: 465-474","DOI":"10.1161\/ATVBAHA.120.315291"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Kelsey MD, Mulder H, Chiswell K, Lampron ZM, Nilles E, Kulinski JP, Joshi PH, Jones WS, Chamberlain AM, Leucker TM, Hwang W, Milks MW, Paranjape A, Obeid JS, Linton MF, Kent ST, Peterson ED, O\u2019Brien EC and Pagidipati NJ: Contemporary patterns of lipoprotein(a) testing and associated clinical care and outcomes. Am J Prev Cardiol, 2023; 14: 100478","DOI":"10.1016\/j.ajpc.2023.100478"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Gautam R, Mehta R, Amari D, Heo J, Wang S, Sung JC, Cristino J and Wong N: A real-world assessment of patient characteristics and treatment patterns among patients with lipoprotein(a) measurement and receiving primary and secondary prevention for cardiovascular disease in the US. J Am Coll Cardiol, 2021; 77: 1563","DOI":"10.1016\/S0735-1097(21)02920-X"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Teramoto T, Uno K, Miyoshi I, Khan I, Gorcyca K, Sanchez RJ, Yoshida S, Mawatari K, Masaki T, Arai H and Yamashita S: Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan. Atherosclerosis, 2016; 251: 248-254","DOI":"10.1016\/j.atherosclerosis.2016.07.001"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokg\u00f6zo\u011flu LS and Catapano AL: Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J, 2022; 43: 3925-3946","DOI":"10.1093\/eurheartj\/ehac361"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, Francis GA, Genest J, Gr\u00e9goire J, Grover SA, Gupta M, Hegele RA, Lau D, Leiter LA, Leung AA, Lonn E, Mancini GBJ, Manjoo P, McPherson R, Ngui D, Pich\u00e9 ME, Poirier P, Sievenpiper J, Stone J, Ward R and Wray W: 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can J Cardiol, 2021; 37: 1129-1150","DOI":"10.1016\/j.cjca.2021.03.016"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Okamura T, Tsukamoto K, Arai H, Fujioka Y, Ishigaki Y, Koba S, Ohmura H, Shoji T, Yokote K, Yoshida H, Yoshida M, Deguchi J, Dobashi K, Fujiyoshi A, Hamaguchi H, Hara M, Harada-Shiba M, Hirata T, Iida M, Ikeda Y, Ishibashi S, Kanda H, Kihara S, Kitagawa K, Kodama S, Koseki M, Maezawa Y, Masuda D, Miida T, Miyamoto Y, Nishimura R, Node K, Noguchi M, Ohishi M, Saito I, Sawada S, Sone H, Takemoto M, Wakatsuki A and Yanai H: Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022. J Atheroscler Thromb, 2024; 31: 641-853","DOI":"10.5551\/jat.GL2022"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Nago N, Kayaba K, Hiraoka J, Matsuo H, Goto T, Kario K, Tsutsumi A, Nakamura Y and Igarashi M: Lipoprotein(a) Levels in the Japanese Population: Influence of Age and Sex, and Relation to Atherosclerotic Risk Factors: The Jichi Medical School Cohort Study. American Journal of Epidemiology, 1995; 141: 815-821","DOI":"10.1093\/oxfordjournals.aje.a117516"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Hopewell JC, Haynes R and Baigent C: The role of lipoprotein (a) in chronic kidney disease. J Lipid Res, 2018; 59: 577-585","DOI":"10.1194\/jlr.R083626"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Enkhmaa B and Berglund L: Non-genetic influences on lipoprotein(a) concentrations. Atherosclerosis, 2022; 349: 53-62","DOI":"10.1016\/j.atherosclerosis.2022.04.006"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Frischmann ME, Kronenberg F, Trenkwalder E, Schaefer JR, Schweer H, Dieplinger B, Koenig P, Ikewaki K and Dieplinger H: In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int, 2007; 71: 1036-1043","DOI":"10.1038\/sj.ki.5002131"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Ye Z, Haycock PC, Gurdasani D, Pomilla C, Boekholdt SM, Tsimikas S, Khaw K-T, Wareham NJ, Sandhu MS and Forouhi NG: The Association Between Circulating Lipoprotein(a) and Type 2 Diabetes: Is It Causal? Diabetes, 2013; 63: 332-342","DOI":"10.2337\/db13-1144"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Mora S, Kamstrup PR, Rifai N, Nordestgaard BG, Buring JE and Ridker PM: Lipoprotein(a) and risk of type 2 diabetes. Clin Chem, 2010; 56: 1252-1260","DOI":"10.1373\/clinchem.2010.146779"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Paige E, Masconi KL, Tsimikas S, Kronenberg F, Santer P, Weger S, Willeit J, Kiechl S and Willeit P: Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature. Cardiovasc Diabetol, 2017; 16: 38","DOI":"10.1186\/s12933-017-0520-z"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Kostner KM and Kostner GM: Lp(a) and the Risk for Cardiovascular Disease: Focus on the Lp(a) Paradox in Diabetes Mellitus. Int J Mol Sci, 2022; 23: 3584","DOI":"10.3390\/ijms23073584"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Tsimikas S, Gordts P, Nora C, Yeang C and Witztum JL: Statin therapy increases lipoprotein(a) levels. Eur Heart J, 2020; 41: 2275-2284","DOI":"10.1093\/eurheartj\/ehz310"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Shah NP, Pajidipati NJ, McGarrah RW, Navar AM, Vemulapalli S, Blazing MA, Shah SH, Hernandez AF and Patel MR: Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations. The American Journal of Cardiology, 2020; 126: 94-102","DOI":"10.1016\/j.amjcard.2020.03.043"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM, Yeang C and Koschinsky ML: Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022; 42: e48-e60","DOI":"10.1161\/ATV.0000000000000147"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Moriarty PM, Moryusef A, Pordy R, Roe MT, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG and Schwartz GG: Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. J Am Coll Cardiol, 2020; 75: 133-144","DOI":"10.1016\/j.jacc.2019.10.057"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Carlson LA, Hamsten A and Asplund A: Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med, 1989; 226: 271-276","DOI":"10.1111\/j.1365-2796.1989.tb01393.x"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Matsunaga A, Handa K, Mori T, Moriyama K, Hidaka K, Yuki M, Sasaki J and Arakawa K: Effects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary hypercholesterolemia. Atherosclerosis, 1992; 94: 241-248","DOI":"10.1016\/0021-9150(92)90249-G"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Teramoto T, Yamada N, Shimano H, Oka Y, Itakura H, Saito Y, Morisaki N, Shirai K, Ishikawa T, Tada N, Ito H, Yamanouchi T, Matsushima T, Kawakami M, Murase T, Okubo M, Totsuka Y and Kikuchi M: Dose-dependent effect of niceritrol on plasma lipoprotein-a. Scand J Clin Lab Invest, 1996; 56: 359-365","DOI":"10.3109\/00365519609090588"},{"key":"48","unstructured":"48) Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, L\u00f3pez-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD and Gabriel Steg P: Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. J Am Coll Cardiol, 2021; 78: 421-433"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/32\/4\/32_64953\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T04:41:07Z","timestamp":1743828067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/32\/4\/32_64953\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.64953","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"article-number":"64953"}}